El-Kassar N, Kalfon P, Fromont P, Vezinet C, Godeau B, Duedari N, Bierling P
Laboratoire d'Immunologie Leuco-plaquettaire, Centre de Transfusion, Hopital Henri Mondor, Créteil, France.
Br J Haematol. 1996 May;93(2):427-31. doi: 10.1046/j.1365-2141.1996.5211064.x.
Fusidic acid is used in hospitals as second-line therapy for multidrug-resistant staphylococcal infections. We report the first fully documented case of fusidic acid induced thrombocytopenia, in a 48-year-old patient. The thrombocytopenia was abrupt and severe but resolved spontaneously 7 d after drug withdrawal. The thrombocytopenia transiently relapsed 6 d later, when fusidic acid was reintroduced. Haemorrhagic signs were observed, but no severe bleeding occurred. Platelet transfusions failed to increase the platelet count. We detected an IgG platelet antibody in the patient's serum, that specifically recognized platelet glycoprotein IIb/IIIa only in the presence of fusidic acid. Fusidic acid induced thrombocytopenia should be considered as a possible cause for the thrombocytopenia frequently seen in the intensive care setting.
夫西地酸在医院中用作耐多药葡萄球菌感染的二线治疗药物。我们报告了首例有完整记录的夫西地酸诱导的血小板减少症病例,患者为一名48岁的男性。血小板减少症突发且严重,但在停药7天后自行缓解。6天后重新使用夫西地酸时,血小板减少症短暂复发。观察到有出血迹象,但未发生严重出血。输注血小板未能提高血小板计数。我们在患者血清中检测到一种IgG血小板抗体,该抗体仅在夫西地酸存在的情况下特异性识别血小板糖蛋白IIb/IIIa。夫西地酸诱导的血小板减少症应被视为重症监护环境中常见血小板减少症的可能原因。